Highly Prescribed Drug Gets FDA Green Light Despite 4-Fold Higher Risk of Death

Contact Your Elected Officials
The Epoch Times Header

The FDA approved a drug already used in nursing homes, but experts are concerned about its potentially lethal effects.

A questionable green light from the U.S. Food and Drug Administration (FDA). An unproven drug frequently used in nursing homes. Medical experts left confused and concerned.

This is the story surrounding brexpiprazole, branded as Rexulti: the first antipsychotic approved to treat agitation in Alzheimer’s patients despite alarmingly high death rates and poor results in clinical trials.

Patients prescribed brexpiprazole faced a fourfold increased risk of dying compared to people who didn’t take the drug, according to an investigation published in the British Medical Journal (BMJ).

For medical professionals, the FDA’s move raises troubling questions about efficacy, safety, and regulatory diligence.

Watchdog Group Flags Dangers as FDA OKs Alzheimer’s Drug

In an open letter (pdf) from May 3, Nina Zeldes, who has a doctorate in medical anthropology and is a drug safety advocate and researcher for Public Citizen, a consumer advocacy organization, urged the FDA to reject the drug manufacturer’s bid. She argued that the drug has no meaningful benefits and increases patients’ risk of harm.

Approving ineffective drugs erodes public trust and gives false hope to families of Alzheimer’s patients, Ms. Zeldes wrote. Patients need to trust that FDA-approved drugs are safe and effective, she added.

Ms. Zeldes also noted that up to 21 percent of nursing home residents already receive risky antipsychotics, citing a New York Times investigation. According to Ms. Zeldes, approving brexpiprazole could increase the use of these potentially deadly drugs.

However, one week later, on May 11, the FDA approved brexpiprazole to treat agitation in Alzheimer’s patients, citing clinical trials showing “statistically significant and clinically meaningful improvements.”

What Did the Clinical Trials Really Show?

The efficacy of drugs for treating Alzheimer’s dementia is based on a scale called the Cohen-Mansfield Agitation Inventory (CMAI) (pdf) that measures 29 behaviors. Caregivers assign a score of 1 to 7 for each statement for a total score of 29 to 203. Some behaviors listed on the scale include how often a patient:

  • Hits, kicks, and screams.
  • Is restless or paces aimlessly.
  • Screams or curses.
  • Repeatedly asks the same question.
  • Complains or is excessively negative.

To determine effectiveness, a patient’s score must change by a value of 17 after 12 weeks of an intervention to be of clinical value. However, the brexpiprazole trials showed only a 5.3-point maximum reduction in CMAI scores, according to the open letter—far below the efficacy threshold.

Brexpiprazole also increased mortality risk. Over 16 weeks, death rates were four times higher among those prescribed the drug versus placebo. 

Furthermore, common adverse side effects include urinary tract infection, sleepiness, insomnia, and higher incidences of cardiovascular events, Ms. Zeldes added.

By Mary Gillis

Read Full Article on TheEpochTimes.com

The Epoch Times
The Epoch Timeshttps://www.theepochtimes.com/
Tired of biased news? The Epoch Times is truthful, factual news that other media outlets don't report. No spin. No agenda. Just honest journalism like it used to be.

Obama Floats ‘New Forms of [State-Controlled] Journalism’

Notorious nemesis of civil liberties one and all, Barack Obama, ]apparently endorses a heavy state hand in the “regulation” of information.

Privilege Is Financial, Not Racial

If we stay divided by race, we’ll keep fighting each other while the true elites of all races thrive unseen, counting their wealth in comfort.

California Repeats Illinois’ History, PROSECUTE Newsom!

California may have improperly licensed 62,000 illegal aliens as Commercial Driver’s License (CDL) truck drivers.

The Stage Is Set For A US-Instigated Security Dilemma Between The Eurasian Rimland & Heartland

The US sends mixed signals on the Sino-Russo alliance after Trump downplayed concerns while Hegseth said he was ordered to “re-establish deterrence.”

Chambers of Horror

Using a shutdown to legislate is like using a flame thrower to light a candle, it provides light momentarily but destroys everything in its path.

Vance Warns Holiday Travel Could Be ‘Disaster’ If Government Does Not Reopen

Vice President JD Vance warned on Thursday that holiday travel will be a “disaster” if the government shutdown does not end.

Trump Admin Cuts Quota for Refugees, Prioritizes Afrikaners

Trump admin slashed quota for refugees and prioritized Afrikaners “and other victims of illegal or unjust discrimination in their respective homelands.”

DHS: 8,000 Percent Jump in Death Threats Against ICE Officers

DHS reports an 8,000% surge in death threats against U.S. immigration officers, raising alarm over safety concerns for federal personnel.

Federal Judge Weighs Forcing USDA to Pay SNAP Benefits Despite Shutdown

A judge weighed forcing the USDA to use a $5 billion fund to prevent a lapse in the national food stamp program amid looming funding shortfalls.

US, South Korea Finalize Trade Deal Reducing Tariffs, Boosting American Investment

The U.S. and South Korea finalized a major trade deal on Oct. 29 as President Trump wrapped up the final hours of his Asian tour on the Korean Peninsula.

Trump, Japanese PM Sign Critical Minerals, Rare Earths Deal

The U.S. president visited Tokyo on the second leg...

Trump Hikes Canada’s Tariffs by 10 Percent for Not Pulling Anti-Tariff Ad Immediately

Trump announced he will increase tariffs on Canada by 10% after ad by provincial government of Ontario misrepresented President Reagan’s speech on tariffs.

Trump Rolls Back Emissions Rules on Copper Smelters

President Trump issued a proclamation aimed at reversing a Biden-era environmental rule that enforced stricter air emission standards on copper smelters.
spot_img

Related Articles

Popular Categories

MAGA Business Central